The prognostic value of the systemic immune inflammation index in patients with IgA nephropathy

References

• Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2(1):16001. doi: 10.1038/nrdp.2016.1.
   PubMedGoogle Scholar
• Barbour SJ, Coppo R, Zhang H, International IgA Nephropathy Network, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–952. doi: 10.1001/jamainternmed.2019.0600.
   PubMed Web of Science ®Google Scholar
• Rauen T, Floege J. Inflammation in IgA nephropathy. Pediatr Nephrol. 2017;32(12):2215–2224. doi: 10.1007/s00467-017-3628-1.
   PubMed Web of Science ®Google Scholar
• Barratt J, Alice CS, Karen M, et al. Immunopathogenesis of IgAN. Semin Immunopathol. 2007;29(4):427–443. doi: 10.1007/s00281-007-0089-9.
   PubMed Web of Science ®Google Scholar
• Geraghty JR, Lung TJ, Hirsch Y, et al. Systemic immune-inflammation index predicts delayed cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2021;89(6):1071–1079. doi: 10.1093/neuros/nyab354.
   PubMed Web of Science ®Google Scholar
• Engin M, Aydin U, Caran Karaoglu EH, et al. A simple predictive marker of inflammation: systemic immune-inflammation index. J Artif Organs. 2023;26(3):251–252. doi: 10.1007/s10047-022-01361-0.
   PubMed Web of Science ®Google Scholar
• Kars A, Sahin A, Kılıc K, et al. Systemic immune inflammation index in differentiated thyroid cancers. Acta Otorhinolaryngol Ital. 2022;42(2):150–154. doi: 10.14639/0392-100X-N1665.
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi: 10.3748/wjg.v23.i34.6261.
   PubMed Web of Science ®Google Scholar
• Kazan DE, Kazan S. Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathy. Eur Rev Med Pharmacol Sci. 2023;27(2):642–648. doi: 10.26355/eurrev_202301_31065.
   PubMed Web of Science ®Google Scholar
• Magistroni R, D’Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–989. doi: 10.1038/ki.2015.252.
   PubMed Web of Science ®Google Scholar
• Leung JCK, Lai KN, Tang SCW. Role of mesangial-podocytic-tubular cross-talk in IgA nephropathy. Semin Nephrol. 2018;38(5):485–495. doi: 10.1016/j.semnephrol.2018.05.018.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan X, Zhao T, et al. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice. Clin Exp Immunol. 2017;189(1):60–70. doi: 10.1111/cei.12961.
   PubMed Web of Science ®Google Scholar
• Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol. 2015;10(9):1636–1650. doi: 10.2215/CJN.06230614.
   PubMed Web of Science ®Google Scholar
• Tortajada A, Gutierrez E, Pickering MC, et al. The role of complement in IgA nephropathy. Mol Immunol. 2019;114:123–132. doi: 10.1016/j.molimm.2019.07.017.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Galdiero MR, Del Prete D, et al. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377–394. doi: 10.1007/s00281-013-0374-8.
   PubMed Web of Science ®Google Scholar
• Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12(1):58. doi: 10.1186/1477-7819-12-58.
   PubMedGoogle Scholar
• Kedziora-Kornatowska KZ. Production of superoxide and nitric oxide by granulocytes in non-insulin-dependent diabetic patients with and without diabetic nephropathy. IUBMB Life. 1999;48(3):359–362. doi: 10.1080/713803522.
   PubMed Web of Science ®Google Scholar
• Fellström BC, Barratt J, Cook H, NEFIGAN Trial Investigators., et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117–2127. doi: 10.1016/S0140-6736(17)30550-0.
   PubMed Web of Science ®Google Scholar
• Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997;51(4):1257–1264. doi: 10.1038/ki.1997.171.
   PubMed Web of Science ®Google Scholar
• Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016;26(3):372–376. doi: 10.3109/14397595.2015.1091136.
   PubMed Web of Science ®Google Scholar
• Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol. 2003;21(1):177–204. doi: 10.1146/annurev.immunol.21.120601.141011.
   PubMedGoogle Scholar
• Perše M, Večerić-Haler Ž. The role of IgA in the pathogenesis of IgA nephropathy. Int J Mol Sci. 2019;20(24):6199. doi: 10.3390/ijms20246199.
   PubMed Web of Science ®Google Scholar
• Akkaya E, Gul M, Ugur M. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014;177(2):597–598. doi: 10.1016/j.ijcard.2014.08.143.
   PubMed Web of Science ®Google Scholar
• Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668–669. doi: 10.1111/hdi.12058.
   PubMed Web of Science ®Google Scholar
• Villarreal JZ, Pérez-Anker J, Puig S, et al. Ex vivo confocal microscopy detects basic patterns of acute and chronic lesions using fresh kidney samples. Clin Kidney J. 2023;16(6):1005–1013. doi: 10.1093/ckj/sfad019.
   PubMed Web of Science ®Google Scholar
• Tunnicliffe DJ, Reid S, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.
   PubMedGoogle Scholar